Ablative Solutions, Inc., a Kalamazoo, MI-based clinical stage company, completed an approximately $9.5m Series B financing.
The round was led by BioStar Ventures and Michigan Accelerator Fund, with participation from founders and angel investors.
Founded by CEO Tim Fischell and David Fischell, and led by President Vartan Ghazarossian, PhD, Ablative Solutions (ASI) has developed a device, the Peregrine System™, which delivers a chemical treatment to the outer layer of the renal artery, where the sympathetic nerves reside.
The company, which also has offices in Menlo Park, CA, is currently now engaged in early clinical evaluations.
FinSMEs
04/02/2014